Alnylam Pharmaceuticals, Inc. (ALNY) Dividend History

Company News

• Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case

  The U.S. Court of Appeals for the Federal Circuit affirmed a district court's finding of noninfringement in favor of Moderna in its patent battle with Alnylam over mRNA-based COVID-19 vaccine technology. The court ruled that Alnylam's patents were not infringed by Moderna's use of the SM-102 lipid in its Spikevax COVID-19 vaccine.

  Benzinga

  Featured Companies: MRNA
• Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight

  The Huntington's disease treatment market is poised for significant growth, driven by rising prevalence rates, advancements in gene-targeting and disease-modifying therapies, and a robust clinical pipeline addressing critical unmet needs.

  GlobeNewswire Inc.

  Featured Companies: ANNX
• Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk

  Alnylam Pharmaceuticals reported a Q1 2025 earnings beat and affirmed its FY2025 sales guidance. Analysts highlighted the strong launch potential of Amvuttra and limited tariff risk due to the company's U.S.-based manufacturing and IP.

  Benzinga

  Featured Companies: BBIO
• Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill?

  Pfizer discontinued development of an experimental weight-management pill, highlighting the risks of drug development. The company also faces upcoming patent expirations for key products and a potential slowdown in FDA approvals due to staffing changes at the agency.

  The Motley Fool

  Featured Companies: BBIO BMY PFE
• FDA Approves Sanofi's Hemophilia Drug

  The FDA has approved Sanofi's Qfitlia (fitusiran), the first antithrombin-lowering therapy for routine prophylaxis to prevent or reduce bleeding episodes in hemophilia patients. The approval is based on data showing significant reduction in annualized bleeding rates.

  Benzinga